

Axel H Schönthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7497937/publications.pdf>

Version: 2024-02-01

144
papers

11,964
citations

44069

48
h-index

26613

107
g-index

147
all docs

147
docs citations

147
times ranked

21193
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. <i>Cell</i> , 1988, 54, 325-334.	28.9	637
3	The Unfolded Protein Response Regulator GRP78/BiP as a Novel Target for Increasing Chemosensitivity in Malignant Gliomas. <i>Cancer Research</i> , 2007, 67, 9809-9816.	0.9	392
4	Endoplasmic Reticulum Stress: Its Role in Disease and Novel Prospects for Therapy. <i>Scientifica</i> , 2012, 2012, 1-26.	1.7	276
5	Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. <i>Blood</i> , 2009, 113, 5927-5937.	1.4	265
6	Posttranscriptional regulation of c-fos mRNA expression. <i>Nucleic Acids Research</i> , 1987, 15, 1643-1659.	14.5	224
7	Mechanisms of G2 Arrest in Response to Overexpression of p53. <i>Molecular Biology of the Cell</i> , 1999, 10, 3607-3622.	2.1	169
8	Role of serine/threonine protein phosphatase 2A in cancer. <i>Cancer Letters</i> , 2001, 170, 1-13.	7.2	168
9	Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. <i>Biochemical Pharmacology</i> , 2013, 85, 653-666.	4.4	160
10	Stress Chaperone GRP78/BiP Confers Chemoresistance to Tumor-Associated Endothelial Cells. <i>Molecular Cancer Research</i> , 2008, 6, 1268-1275.	3.4	146
11	Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. <i>Neurosurgical Focus</i> , 2015, 38, E12.	2.3	143
12	HIV-1 Protease Inhibitors Nelfinavir and Atazanavir Induce Malignant Glioma Death by Triggering Endoplasmic Reticulum Stress. <i>Cancer Research</i> , 2007, 67, 10920-10928.	0.9	136
13	Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. <i>Neurosurgical Focus</i> , 2014, 37, E12.	2.3	136
14	Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib. <i>Cancer Research</i> , 2008, 68, 843-851.	0.9	131
15	Autoregulation of Protein Phosphatase Type 2A Expression. <i>Journal of Biological Chemistry</i> , 1998, 273, 19019-19024.	3.4	129
16	Expression of Human Prostatic Acid Phosphatase Correlates with Androgen-stimulated Cell Proliferation in Prostate Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 1998, 273, 5939-5947.	3.4	122
17	Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1262-1275.	4.1	120
18	Role of PP2A in intracellular signal transduction pathways. <i>Frontiers in Bioscience - Landmark</i> , 1998, 3, d1262-1273.	3.0	107

#	ARTICLE	IF	CITATIONS
19	Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. <i>Journal of Neurosurgery</i> , 2007, 106, 455-462.	1.6	102
20	Endoplasmic reticulum stress and autophagy as targets for cancer therapy. <i>Cancer Letters</i> , 2009, 275, 163-169.	7.2	100
21	Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. <i>Oncogene</i> , 2001, 20, 2134-2143.	5.9	98
22	Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. <i>Cancer Letters</i> , 2012, 326, 143-154.	7.2	98
23	Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. <i>British Journal of Cancer</i> , 2007, 97, 1465-1468.	6.4	96
24	Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. <i>Cancer Letters</i> , 2011, 302, 100-108.	7.2	91
25	p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53. <i>Journal of Biological Chemistry</i> , 2001, 276, 1998-2006.	3.4	90
26	Increased Survivin Expression Confers Chemoresistance to Tumor-Associated Endothelial Cells. <i>American Journal of Pathology</i> , 2008, 173, 575-585.	3.8	84
27	Inhibitory Phosphorylation of PP1 Catalytic Subunit during the G1/S Transition. <i>Journal of Biological Chemistry</i> , 1999, 274, 29470-29475.	3.4	80
28	Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. <i>Molecular Cancer</i> , 2006, 5, 19.	19.2	80
29	Dimethyl-Celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on burkitt's lymphoma in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2005, 4, 571-582.	3.4	78
30	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 197-208.	4.1	78
31	Differential Effects of Selective COX-2 Inhibitors on Cell Cycle Regulation and Proliferation of Glioblastoma Cell Lines. <i>Cancer Biology and Therapy</i> , 2004, 3, 55-62.	3.4	77
32	Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2462-2472.	4.1	75
33	Activation of p53-p21 Pathway in Response to Disruption of Cell-Matrix Interactions. <i>Journal of Biological Chemistry</i> , 1997, 272, 29091-29098.	3.4	74
34	Adverse effects of concentrated green tea extracts. <i>Molecular Nutrition and Food Research</i> , 2011, 55, 874-885.	3.3	74
35	EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. <i>International Journal of Cancer</i> , 2006, 119, 1236-1248.	5.1	69
36	Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells. <i>Cancer Research</i> , 2006, 66, 11115-11119.	0.9	69

#	ARTICLE	IF	CITATIONS
37	Peroxisome Proliferator-activated Receptor β Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase C δ Pathway in Vascular Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 47650-47657.	3.4	67
38	The Type IV Phosphodiesterase Inhibitor Rolipram Induces Expression Inhibitors p21Cip1 and p27Kip1, Resulting in Growth Inhibition, Increased Differentiation, and Subsequent Apoptosis of Malignant A-172 Glioma Cells. <i>Cancer Biology and Therapy</i> , 2002, 1, 268-276.	3.4	67
39	Induction of p21 Mediated by Reactive Oxygen Species Formed during the Metabolism of Aziridinybenzoquinones by HCT116 Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 31915-31921.	3.4	63
40	Increased Expression of TATA-Binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis. <i>Molecular and Cellular Biology</i> , 2003, 23, 3043-3051.	2.3	62
41	Targeting endoplasmic reticulum stress for cancer therapy. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 412-431.	2.1	62
42	COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. <i>Molecular Cancer</i> , 2008, 7, 38.	19.2	61
43	Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. <i>Neurosurgical Focus</i> , 2006, 20, E21.	2.3	59
44	Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3905.	4.1	57
45	Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. <i>Blood</i> , 2005, 106, 4330-4338.	1.4	56
46	Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. <i>Cancer Letters</i> , 2012, 325, 63-71.	7.2	54
47	NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2004-2017.	4.1	52
48	Targeting endoplasmic reticulum stress for cancer therapy. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 412.	2.1	50
49	Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. <i>Cancer Letters</i> , 2009, 282, 87-97.	7.2	49
50	Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 ⁺ T-lymphocyte counts. <i>CNS Oncology</i> , 2018, 7, CNS22.	3.0	49
51	CCAAT/Enhancer Binding Protein Homologous Protein-Dependent Death Receptor 5 Induction and Ubiquitin/Proteasome-Mediated Cellular FLICE-Inhibitory Protein Down-Regulation Contribute to Enhancement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Dimethyl-Celecoxib in Human Non-Small-Cell Lung Cancer Cells. <i>Molecular Pharmacology</i> , 2007, 72, 1269-1279.	2.3	45
52	Glioma-associated endothelial cells are chemoresistant to temozolomide. <i>Journal of Neuro-Oncology</i> , 2009, 95, 13-22.	2.9	44
53	A Novel Temozolomide-Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells <i>In Vitro</i> and Intracranial Triple-Negative Tumor Growth <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1181-1193.	4.1	43
54	Noscapine inhibits tumor growth in TMZ-resistant gliomas. <i>Cancer Letters</i> , 2011, 312, 245-252.	7.2	41

#	ARTICLE	IF	CITATIONS
55	Anticancer Quinones Induce pRb-Preventable G2/M Cell Cycle Arrest and Apoptosis. <i>Free Radical Biology and Medicine</i> , 1998, 24, 848-854.	2.9	40
56	Proliferation of Lacrimal Gland Acinar Cells in Primary Culture. Stimulation by Extracellular Matrix, EGF, and DHT. <i>Experimental Eye Research</i> , 2000, 70, 639-649.	2.6	39
57	Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma. <i>Oncology Letters</i> , 2018, 15, 1263-1270.	1.8	38
58	Regulation of gene expression by serine/threonine protein phosphatases. <i>Seminars in Cancer Biology</i> , 1995, 6, 239-248.	9.6	37
59	Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. <i>American Journal of Cancer Research</i> , 2015, 5, 1580-93.	1.4	37
60	Effect of Reproductive Hormones on Ovarian Epithelial Tumors: I. Effect. <i>Cancer Biology and Therapy</i> , 2002, 1, 300-306.	3.4	35
61	Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. <i>Neurosurgical Focus</i> , 2006, 20, E20.	2.3	34
62	Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model. <i>Journal of Neurosurgery</i> , 2018, 128, 695-700.	1.6	34
63	Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1463.	4.1	33
64	The intracellular genistein metabolite 5,7,3,4-tetrahydroxyisoflavone mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway. <i>Free Radical Biology and Medicine</i> , 2006, 41, 1225-1239.	2.9	31
65	Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. <i>Molecular and Cellular Biochemistry</i> , 2000, 203, 59-71.	3.1	29
66	Celecoxib transiently inhibits cellular protein synthesis. <i>Biochemical Pharmacology</i> , 2008, 75, 395-404.	4.4	29
67	Nuclear protooncogene products: fine-tuned components of signal transduction pathways. <i>Cellular Signalling</i> , 1990, 2, 215-225.	3.6	26
68	Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 1406-1412.	0.8	26
69	Glioma-associated endothelial cells show evidence of replicative senescence. <i>Experimental Cell Research</i> , 2007, 313, 1192-1202.	2.6	26
70	Repositioning of Verrucosidin, a Purported Inhibitor of Chaperone Protein GRP78, as an Inhibitor of Mitochondrial Electron Transport Chain Complex I. <i>PLoS ONE</i> , 2013, 8, e65695.	2.5	26
71	A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. <i>Cancer Letters</i> , 2016, 371, 240-250.	7.2	24
72	Perillyl alcohol, a pleiotropic natural compound suitable for brain tumor therapy, targets free radicals. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 285-297.	2.3	24

#	ARTICLE	IF	CITATIONS
73	Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. <i>Cancer Letters</i> , 2011, 304, 33-40.	7.2	23
74	A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. <i>Cancer Letters</i> , 2015, 358, 144-151.	7.2	22
75	Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. <i>Neurosurgical Focus</i> , 2015, 38, E8.	2.3	22
76	An Update of the Mammalian UV Response: Gene Regulation and Induction of a Protective Function. , 1989, , 149-165.		22
77	Endoplasmic reticulum stress-inducible protein GRP94 is associated with an Mg ²⁺ -dependent serine kinase activity modulated by Ca ²⁺ and GRP78/BiP. , 1997, 170, 115-129.		21
78	Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. <i>Leukemia Research</i> , 2010, 34, 250-253.	0.8	21
79	Antiangiogenic Activities of 2,5-Dimethyl-Celecoxib on the Tumor Vasculature. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 631-641.	4.1	21
80	Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response. <i>Current Pharmaceutical Design</i> , 2011, 17, 2428-2438.	1.9	21
81	Bioorthogonal Profiling of a Cancer Cell Proteome Identifies a Large Set of 3-Bromopyruvate Targets beyond Glycolysis. <i>ACS Chemical Biology</i> , 2018, 13, 3054-3058.	3.4	21
82	Positive Regulation of cdc2 Gene Activity by Protein Phosphatase Type 2A. <i>Journal of Biological Chemistry</i> , 1996, 271, 5988-5992.	3.4	19
83	Potential Misidentification of Cyclooxygenase-2 by Western Blot Analysis and Prevention Through the Inclusion of Appropriate Controls. <i>Molecular Biotechnology</i> , 2006, 34, 329-336.	2.4	19
84	NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 625-637.	4.1	19
85	NEO100 enables brain delivery of blood-brain barrier impermeable therapeutics. <i>Neuro-Oncology</i> , 2021, 23, 63-75.	1.2	19
86	Exploiting Cyclooxygenase-(in)Dependent Properties of COX-2 Inhibitors for Malignant Glioma Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 450-461.	1.7	19
87	Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas. , 2016, 7, 1.		19
88	Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. <i>Journal of Neurosurgery</i> , 2011, 114, 689-694.	1.6	18
89	Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. <i>Journal of Biomedical Science</i> , 2015, 22, 71.	7.0	18
90	Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review. <i>Biochemical Pharmacology</i> , 2020, 181, 114149.	4.4	18

#	ARTICLE	IF	CITATIONS
91	Gene amplification and multidrug resistance induced by the phosphatase-inhibitory tumor promoter, okadaic acid. <i>Carcinogenesis</i> , 1995, 16, 637-641.	2.8	17
92	Reduction of Ha-ras-induced cellular transformation by elevated expression of protein phosphatase type 2A. , 1999, 24, 246-254.		17
93	Heat shock protein-90alpha (Hsp90 α) stabilizes hypoxia-inducible factor-1 α (HIF-1 α) in support of spermatogenesis and tumorigenesis. <i>Cancer Gene Therapy</i> , 2021, 28, 1058-1070.	4.6	17
94	Expression and Activity of Cell Cycle-Regulatory Proteins in Normal and Transformed Corneal Endothelial Cells. <i>Experimental Eye Research</i> , 1999, 68, 531-539.	2.6	16
95	Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. <i>International Journal of Cancer</i> , 2012, 130, 2495-2504.	5.1	16
96	Potent Mimicry of Fibronectin-induced Intracellular Signaling in Glioma Cells by the Homodimeric Snake Venom Disintegrin Contortrostatin. <i>Neurosurgery</i> , 2005, 57, 141-153.	1.1	15
97	Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model. <i>Neurosurgical Focus</i> , 2006, 21, 1-8.	2.3	15
98	Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. <i>Journal of Biomedical Science</i> , 2007, 14, 647-662.	7.0	15
99	The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model. <i>Journal of Neurosurgery</i> , 2005, 103, 526-537.	1.6	12
100	Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. <i>Biochemical Pharmacology</i> , 2011, 82, 600-609.	4.4	12
101	The Monoterpenoid Perillyl Alcohol: Anticancer Agent and Medium to Overcome Biological Barriers. <i>Pharmaceutics</i> , 2021, 13, 2167.	4.5	12
102	Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. <i>Journal of Neurosurgery</i> , 2015, 123, 362-372.	1.6	11
103	A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells. <i>Cancer Letters</i> , 2017, 400, 161-174.	7.2	11
104	Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. <i>Neuro-Oncology</i> , 2021, 23, 1656-1667.	1.2	11
105	Efficient brain targeting and therapeutic intracranial activity of bortezomib through intranasal co-delivery with NEO100 in rodent glioblastoma models. <i>Journal of Neurosurgery</i> , 2020, 132, 959-967.	1.6	11
106	Intravenous delivery of microRNA-133b along with Argonaute-2 enhances spinal cord recovery following cervical contusion in mice. <i>Spine Journal</i> , 2020, 20, 1138-1151.	1.3	10
107	Induction of Apoptosis by Celecoxib in Cell Culture: An Uncertain Role for Cyclooxygenase-2: Figure 1.. <i>Cancer Research</i> , 2007, 67, 5575-5576.	0.9	9
108	Role of p53 in aziridinylbenzoquinone-induced p21waf1 expression. <i>Oncogene</i> , 1998, 17, 357-365.	5.9	8

#	ARTICLE	IF	CITATIONS
109	Induction of protein phosphatase type 2A in response to disruption of cell-matrix interactions. <i>Journal of Cellular Physiology</i> , 2000, 182, 88-96.	4.1	8
110	Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. <i>Cancers</i> , 2018, 10, 362.	3.7	8
111	Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab005.	0.7	8
112	Activation of the C-fos promoter by increased internal pH. <i>Journal of Cellular Biochemistry</i> , 1995, 57, 630-640.	2.6	7
113	Analyzing Gene Expression with the Use of Serine/Threonine Phosphatase Inhibitors. , 1998, 93, 35-40.		7
114	Suppression of the transformed phenotype and induction of differentiation-like characteristics in cultured ovarian tumor cells by chronic treatment with progesterone. <i>Molecular Carcinogenesis</i> , 2003, 38, 160-169.	2.7	7
115	Measuring Cyclin-Dependent Kinase Activity. , 2004, 281, 105-124.		7
116	Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl Alcohol Conjugated to Rolipram. <i>International Journal of Molecular Sciences</i> , 2018, 19, 277.	4.1	7
117	Cytotoxic impact of a perillyl alcohol-temozolomide conjugate, NEO212, on cutaneous T-cell lymphoma in vitro. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989156.	3.2	7
118	The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 517-530.	4.1	7
119	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. <i>PLoS ONE</i> , 2020, 15, e0238238.	2.5	7
120	Heterogeneous Responses and Isoform Compensation Dim the Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer. <i>Molecular and Cellular Biology</i> , 2022, 42, MCB0045921.	2.3	7
121	Pharmacokinetic properties of the temozolomide perillyl alcohol conjugate (NEO212) in mice. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa160.	0.7	6
122	Expression of c-Jun Proto-oncogene in Corneal Endothelium. <i>Experimental Eye Research</i> , 1994, 59, 335-341.	2.6	5
123	Changes in cytoskeletal organization in polyoma middle T antigen-transformed fibroblasts: Involvement of protein phosphatase 2A and src tyrosine kinases. <i>Cytoskeleton</i> , 2000, 47, 253-268.	4.4	5
124	Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats. <i>Drug Testing and Analysis</i> , 2020, 12, 268-279.	2.6	5
125	NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo. <i>Oncotarget</i> , 2018, 9, 37026-37041.	1.8	5
126	Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor. <i>BMC Molecular Biology</i> , 2002, 3, 11.	3.0	4

#	ARTICLE	IF	CITATIONS
127	Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy. , 2020, 11, 389.		4
128	Gene Regulation by Ca ²⁺ -ATPases.. Annals of the New York Academy of Sciences, 1992, 671, 509-511.	3.8	3
129	Patient with Recurrent Glioblastoma Responding Favorably to Ketogenic Diet Combined with Intranasal Delivery of Perillyl Alcohol: A Case Report and Literature Review. Brazilian Neurosurgery, 2017, 36, 194-199.	0.1	3
130	A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide. Frontiers in Oncology, 0, 12, .	2.8	3
131	Inhibition of tumor cell growth by triton X-100 through specific effects on cell-cycle-regulatory components. Journal of Biomedical Science, 2004, 11, 95-103.	7.0	2
132	Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia. Cancers, 2021, 13, 3385.	3.7	2
133	Positive and Negative Regulation of Cell Cycle Progression by Serine/Threonine Protein Phosphatases. , 1994, , 33-40.		2
134	Measuring animal well-being. Nature, 1992, 356, 556-556.	27.8	1
135	Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53. Cancer Res 2003;63:5239-42.. Cancer Research, 2004, 64, 2937-2938.	0.9	1
136	The Role of FOS in Gene Regulation. , 1990, , 77-91.		1
137	Redox Regulation of p21, Role of Reactive Oxygen and Nitrogen Species in Cell Cycle Progression. , 2000, , 311-336.		0
138	Targeting Endoplasmic Reticulum Stress for Malignant Glioma Therapy. , 2009, , 1037-1056.		0
139	Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma. , 2011, , 291-298.		0
140	Regulation of Proto-Oncogene Expression and Rate of Protein Synthesis by the Tumor Promoter Okadaic Acid. , 1991, , 337-341.		0
141	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
142	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
143	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0
144	Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. , 2020, 15, e0238238.		0